Orexo ABORXOF 34 Net Current Asset Value is $0.70 as of Mar. 2026, which is 93% below its 10-year median of 9.86. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 614 Drug Manufacturers companies, Orexo AB ranks better than 67.26% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Orexo AB's net current asset value per share for the quarter that ended in Mar. 2026 was $0.70.
The historical rank and industry rank for Orexo AB's Net Current Asset Value or its related term are showing as below:
ORXOF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.96 Med: 9.86 Max: 23.24
Current: 3.18
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Orexo AB was 23.24. The lowest was 2.96. And the median was 9.86.
ORXOF's Price-to-Net-Current-Asset-Value is ranked better than 67.26% of 614
companies
in the Drug Manufacturers industry
Industry Median: 5.495
vs ORXOF: 3.18
Orexo AB (OTCPK:ORXOF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Orexo AB Net Current Asset Value Related Terms
Orexo AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Orexo AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Orexo AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.70 mean?
Orexo AB (ORXOF) has a Net Current Asset Value of $0.70 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Orexo AB and its competitors. This is 93% below median its historical median of 9.86. Over the past decade, Orexo AB's Net Current Asset Value has ranged from 2.96 to 23.24. According to the industry distribution chart, Orexo AB ranks #201 out of 614 companies in the Drug Manufacturers industry, placing it in the top 32.7%.
Is Orexo AB's Net Current Asset Value too high?
Orexo AB's current Net Current Asset Value of $0.70 is 93% below median its 10-year median of 9.86. Over the past 10 years, this metric has ranged from a low of 2.96 to a high of 23.24. The Drug Manufacturers industry median Net Current Asset Value is 5.50. Orexo AB's value of $0.70 is 87.3% below this industry median. Based on the distribution chart, Orexo AB ranks #201 out of 614 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Net Current Asset Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #201 out of 614 companies for Net Current Asset Value. This puts Orexo AB in the upper half of its industry. The industry median Net Current Asset Value is 5.50. Orexo AB's value of $0.70 is 87.3% below this benchmark. Historically, Orexo AB's own Net Current Asset Value has ranged from 2.96 to 23.24 over the past decade. While the company's 10-year median is 9.86 vs. the industry median of 5.50, Orexo AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.50, based on 614 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current Net Current Asset Value of $0.70 is 87.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Net Current Asset Value is $0.70, which is 93% below median its own 10-year median of 9.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current Net Current Asset Value is $0.70, which is 93% below median its 10-year median of 9.86 and 87.3% below the Drug Manufacturers industry median of 5.50. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Orexo AB (ORXOF), the current Net Current Asset Value is $0.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOF) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOF:
Net Current Asset Value: $0.70 (93% below median its 10-year median of 9.86)
GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
Industry Position: 87.3% below the Drug Manufacturers median (#201 of 614)
No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score
Get the complete analysis for ORXOF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOF has been successfully added to your 
